Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α
Open Access
- 24 February 2014
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 124 (4) , 1794-1809
Abstract
The genes encoding RAS family members are frequently mutated in juvenile myelomonocytic leukemia (JMML) and acute myeloid leukemia (AML). RAS proteins are difficult to target pharmacologically; therefore, targeting the downstream PI3K and RAF/MEK/ERK pathways represents a promising approach to treat RAS-addicted tumors. The p110α isoform of PI3K (encoded by Pik3ca) is an essential effector of oncogenic KRAS in murine lung tumors, but it is unknown whether p110α contributes to leukemia. To specifically examine the role of p110α in murine hematopoiesis and in leukemia, we conditionally deleted p110α in HSCs using the Cre-loxP system. Postnatal deletion of p110α resulted in mild anemia without affecting HSC self-renewal; however, deletion of p110α in mice with KRASG12D-associated JMML markedly delayed their death. Furthermore, the p110α-selective inhibitor BYL719 inhibited growth factor–independent KRASG12D BM colony formation and sensitized cells to a low dose of the MEK inhibitor MEK162. Furthermore, combined inhibition of p110α and MEK effectively reduced proliferation of RAS-mutated AML cell lines and disease in an AML murine xenograft model. Together, our data indicate that RAS-mutated myeloid leukemias are dependent on the PI3K isoform p110α, and combined pharmacologic inhibition of p110α and MEK could be an effective therapeutic strategy for JMML and AML.Keywords
This publication has 52 references indexed in Scilit:
- The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesisGenes & Development, 2012
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaNew England Journal of Medicine, 2012
- Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancerProceedings of the National Academy of Sciences, 2009
- Should individual PI3 kinase isoforms be targeted in cancer?Current Opinion in Cell Biology, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- TSC–mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen speciesJournal of Experimental Medicine, 2008
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- Evidence for functional redundancy of class IA PI3K isoforms in insulin signallingBiochemical Journal, 2007
- The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformationProceedings of the National Academy of Sciences, 2006
- Inducible Gene Targeting in MiceScience, 1995